Imaging Correlates of Differential Expression of Indoleamine 2,3-Dioxygenase in Human Brain Tumors
详细信息 查看全文
- 作者：Carlos E. A. Batista (1) (7)
Csaba Juhász (1) (2) (6) (7)
Otto Muzik (1) (3) (7)
William J. Kupsky (4)
Geoffrey Barger (2) (6)
Harry T. Chugani (1) (2) (3) (7)
Sandeep Mittal (5) (6)
Sandeep Sood (1) (5)
Pulak K. Chakraborty (7)
Diane C. Chugani (1) (3) (7) - 关键词：Glioma ; Positron emission tomography ; Tryptophan ; Indoleamine 2 ; 3 ; Dioxygenase ; Immunohistochemistry
- 刊名：Molecular Imaging and Biology
- 出版年：2009
- 出版时间：November 2009
- 年：2009
- 卷：11
- 期：6
- 页码：460-466
- 全文大小：284KB
- 参考文献：1. Aune TM, Pogue SL (1989) Inhibition of tumor cell growth by interferon-gamma is mediated by two distinct mechanisms dependent upon oxygen tension: induction of tryptophan degradation and depletion of intracellular nicotinamide adenine d inucleotide. J Clin Invest 84:863-75 ternal" href="http://dx.doi.org/10.1172/JCI114247">CrossRef
2. Beutelspacher SC, Tan PH, McClure MO, Larkin DF, Lechler RI, George AJ (2006) Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. Am J Transplant 6:1320-330 ternal" href="http://dx.doi.org/10.1111/j.1600-6143.2006.01324.x">CrossRef
3. Burger PC, Scheithauer BW (eds) (1994) Atlas of tumor pathology: tumors of the central nervous system, 3rd series. Armed Forces Institute of Pathology, Bethesda, MD
4. Burger PC, Scheithauer BW, Vogel FS (eds) (2002) Surgical pathology of the nervous system and its coverings, PC 4th edn. New York: Churchill-Livingstone
5. Burke F, Knowles RG, East N, Balkwill FR (1995) The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma / in vivo. Int J Cancer 60:115-22 ternal" href="http://dx.doi.org/10.1002/ijc.2910600117">CrossRef
6. Chugani DC, Muzik O, Chakraborty P, Mangner T, Chugani HT (1998) Human brain serotonin synthesis capacity measured / in vivo with alpha-[C-11]methyl-L-tryptophan. Synapse 28:33-3 ternal" href="http://dx.doi.org/10.1002/(SICI)1098-2396(199801)28:1<33::AID-SYN5>3.0.CO;2-D">CrossRef
7. Chugani DC, Muzik O (2000) Alpha[C-11]methyl-L-tryptophan PET maps brain serotonin synthesis and kynurenine pathway metabolism. J Cereb Blood Flow Metab 20:2- ternal" href="http://dx.doi.org/10.1097/00004647-200001000-00002">CrossRef
8. Diksic M, Nagahiro S, Sourkes TL, Yamamoto YL (1990) A new method to measure brain serotonin synthesis / in vivo. I. Theory and basic data for a biological model. J Cereb Blood Flow Metab 10:1-2
9. Fenstermaker RA, Ciesielski MJ (2004) Immunotherapeutic strategies for malignant glioma. Cancer Control 11:181-91
10. Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ (2002) Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 101:151-55 ternal" href="http://dx.doi.org/10.1002/ijc.10645">CrossRef
11. Gjedde A (1981) High- and low-affinity transport of D-glucose from blood to brain. J Neurochem 36:1463-471 ternal" href="http://dx.doi.org/10.1111/j.1471-4159.1981.tb00587.x">CrossRef
12. Guillemin GJ, Smythe G, Takikawa O, Brew BJ (2005) Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49(1):15-3 ternal" href="http://dx.doi.org/10.1002/glia.20090">CrossRef
13. Jensen RL, Caamano E, Jensen EM, Couldwell WT (2006) Development of contrast enhancement after long-term observation of a dysembryoplastic neuroepithelial tumor. J Neurooncol 78:59-2 ternal" href="http://dx.doi.org/10.1007/s11060-005-9054-4">CrossRef
14. Jia L, Schweikart K, Tomaszewski J, Page JG, Noker PE, Buhrow SA, Reid JM, Ames MM, Munn DH (2008) Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol 46:203-11 ternal" href="http://dx.doi.org/10.1016/j.fct.2007.07.017">CrossRef
15. Juhasz C, Chugani DC, Muzik O, Wu D, Sloan AE, Barger G, Watson C, Shah AK, Sood S, Ergun EL, Mangner TJ, Chakraborty PK, Kupsky WJ, Chugani HT (2006) / In vivo uptake and metabolism of alpha-[11C]methyl-L-tryptophan in human brain tumors. J Cereb Blood Flow Metab 26:345-57 ternal" href="http://dx.doi.org/10.1038/sj.jcbfm.9600199">CrossRef
16. Kai S, Goto S, Tahara K, Sasaki A, Kawano K, Kitano S (2003) Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth. J Exp Ther Oncol 3:336-45 ternal" href="http://dx.doi.org/10.1111/j.1533-869X.2003.01108.x">CrossRef
17. Kai S, Goto S, Tahara K, Sasaki A, Tone S, Kitano S (2004) Indoleamine 2,3-dioxygenase is necessary for cytolytic activity of natural killer cells. Scand J Immunol 59:177-82 ternal" href="http://dx.doi.org/10.1111/j.0300-9475.2004.01378.x">CrossRef
18. King NJ, Thomas SR (2007) Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol 39:2167-172 ternal" href="http://dx.doi.org/10.1016/j.biocel.2007.01.004">CrossRef
19. Kleihues P, Cavenee WK (eds) (2000) Pathology and genetics of tumours of the nervous system. International Agency for Research on Cancer (IARC) Press, Lyon
20. Kwidzinski E, Bunse J, Kovac AD, Ullrich O, Zipp F, Nitsch R, Bechmann I (2003) IDO (indolamine 2,3-dioxygenase) expression and function in the CNS. Adv Exp Med Biol 527:113-18
21. Kwidzinski E, Bechmann I (2007) IDO expression in the brain: a double-edged sword. J Mol Med 85:1351-359 ternal" href="http://dx.doi.org/10.1007/s00109-007-0229-7">CrossRef
22. L?b S, K?nigsrainer A (2008) Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction? Langenbecks Arch Surg 393:995-003 ternal" href="http://dx.doi.org/10.1007/s00423-007-0245-7">CrossRef
23. L?b S, K?nigsrainer A, Zieker D, Brücher BL, Rammensee HG, Opelz G, Terness P (2009) IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 58:153-57 ternal" href="http://dx.doi.org/10.1007/s00262-008-0513-6">CrossRef
24. Madras BK, Sourkes TL (1965) Metabolism of alpha-methyltryptophan. Biochem Pharmacol 14:1499-506 ternal" href="http://dx.doi.org/10.1016/0006-2952(65)90003-1">CrossRef
25. Mellor AL, Munn DH (1999) Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 20:469-73 ternal" href="http://dx.doi.org/10.1016/S0167-5699(99)01520-0">CrossRef
26. Merchant RE, McVicar DW, Merchant LH, Young HF (1992) Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial. J Neurooncol 12:75-3 ternal" href="http://dx.doi.org/10.1007/BF00172459">CrossRef
27. Munn DH, Mellor AL (2004) IDO and tolerance to tumors. Trends Mol Med 10:15- ternal" href="http://dx.doi.org/10.1016/j.molmed.2003.11.003">CrossRef
28. Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117:1147-4 ternal" href="http://dx.doi.org/10.1172/JCI31178">CrossRef
29. Muzik O, Behrendt DB, Mangner TJ, Chugani HT (1994) Design of a pediatric protocol for quantitative brain FDG studies with PET not requiring invasive blood sampling. J Nucl Med 35:104
30. Muzik O, Chugani DC, Chakraborty P, Mangner T, Chugani HT (1997) Analysis of [C-11]alpha-methyl-tryptophan kinetics for the estimation of serotonin synthesis rate / in vivo. J Cereb Blood Flow Metab 17:659-69 ternal" href="http://dx.doi.org/10.1097/00004647-199706000-00007">CrossRef
31. Ozaki Y, Edelstein MP, Duch DS (1988) Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc Natl Acad Sci USA 85:1242-246 ternal" href="http://dx.doi.org/10.1073/pnas.85.4.1242">CrossRef
32. Patlak CS, Blasberg RG, Fenstermacher JD (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3:1-
33. Quinones-Hinojosa A, Sanai N, Smith JS, McDermott MW (2005) Techniques to assess the proliferative potential of brain tumors. J Neurooncol 74:19-0 ternal" href="http://dx.doi.org/10.1007/s11060-004-5758-0">CrossRef
34. Riesenberg R, Weiler C, Spring O, Eder M, Buchner A, Popp T, Castro M, Kammerer R, Takikawa O, Hatz RA, Stief CG, Hofstetter A, Zimmermann W (2007) Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res 13:6993-002 ternal" href="http://dx.doi.org/10.1158/1078-0432.CCR-07-0942">CrossRef
35. Schr?cksnadel K, Wirleitner B, Winkler C, Fuchs D (2006) Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 364:82-0 ternal" href="http://dx.doi.org/10.1016/j.cca.2005.06.013">CrossRef
36. Schwarcz R, Pellicciari R (2002) Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 303:1-0 ternal" href="http://dx.doi.org/10.1124/jpet.102.034439">CrossRef
37. Stojic J, Hagemann C, Haas S, Herbold C, Kühnel S, Gerngras S, Roggendorf W, Roosen K, Vince GH (2008) Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci Res 60:40-9 ternal" href="http://dx.doi.org/10.1016/j.neures.2007.09.009">CrossRef
38. Suhonen-Polvi H, Ruotsalainen U, Kinnala A, Bergman J, Haaparanta M, Teras M, Makela P, Solin O, Wegelius U (1995) FDG-PET in early infancy: simplified quantification methods to measure cerebral glucose utilization. J Nucl Med 36:1249-254
39. Taylor MW, Feng GS (1991) Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 5:2516-522
40. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van Den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269-274 ternal" href="http://dx.doi.org/10.1038/nm934">CrossRef
41. Vezzani A, Gramsbergen JB, Versari P, Stasi MA, Procaccio F, Schwarcz R (1990) Kynurenic acid synthesis by human glioma. J Neurol Sci 99:51-7 ternal" href="http://dx.doi.org/10.1016/0022-510X(90)90198-V">CrossRef
42. Wolff JE, Wagner S, Reinert C, Gnekow A, Kortmann RD, Kühl J, Van Gool SW (2006) Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol 79:315-21 ternal" href="http://dx.doi.org/10.1007/s11060-006-9147-8">CrossRef - 作者单位：Carlos E. A. Batista (1) (7)
Csaba Juhász (1) (2) (6) (7)
Otto Muzik (1) (3) (7)
William J. Kupsky (4)
Geoffrey Barger (2) (6)
Harry T. Chugani (1) (2) (3) (7)
Sandeep Mittal (5) (6)
Sandeep Sood (1) (5)
Pulak K. Chakraborty (7)
Diane C. Chugani (1) (3) (7)
1. Carman and Ann Adams Department of Pediatrics, School of Medicine, Wayne State University, Detroit, MI, USA
7. PET Center, Children’s Hospital of Michigan, Detroit, MI, USA
2. Department of Neurology, School of Medicine, Wayne State University, Detroit, MI, USA
6. Karmanos Cancer Institute, School of Medicine, Wayne State University, Detroit, MI, USA
3. Department of Radiology, School of Medicine, Wayne State University, Detroit, MI, USA
4. Department of Pathology, School of Medicine, Wayne State University, Detroit, MI, USA
5. Department of Neurosurgery, School of Medicine, Wayne State University, Detroit, MI, USA
文摘
Background Tryptophan catabolism via the kynurenine pathway, mediated by indoleamine 2,3-dioxygenase (IDO), is a mechanism involved in tumor immunoresistance. Positron emission tomography (PET) with α-[11C]methyl-L-tryptophan (AMT) can quantify transport and metabolism of tryptophan in infiltrating gliomas and glioneuronal tumors. In the present study, we investigated whether increased tryptophan metabolism in brain tumors measured by PET is related to expression of IDO in resected brain tumor specimens. Methods IDO expression was assessed by immunohistochemistry in tumor specimens from 15 patients (median age, 34?years) with primary brain tumors who underwent AMT PET scanning before tumor resection. Patterns of IDO expression were compared between low- and high-grade tumors and also to AMT transport and metabolism measured on PET. Results IDO immunoreactivity was seen in tumor cells in six of seven low-grade tumors but only in one of eight high-grade tumors (p--.01); three of these latter tumors showed endothelial staining only. Low-grade neoplasms showed lower transport rate (p-lt;-.01) but higher metabolic rate (p--.003) for AMT as compared to high-grade tumors. AMT metabolic rates were lower in tumor samples with no or minimal IDO expression as compared to those with widespread IDO staining (p--.017). Conclusion Low-grade tumors show widespread IDO expression, while IDO expression in high-grade brain tumors can be absent or largely confined to endothelial cells. AMT PET can be useful to identify brain tumors with different profiles of IDO expression, thus providing a useful imaging marker for emerging treatments targeting tumor IDO activity.